SISRAM MED(01696): Lior Moshe DAYAN will serve as executive director, chairman, chairman of the nomination committee, and authorized representative.

SISRAM MED (01696) announced that as of January 1, 2026, current Executive Director and Chairman of the Board, Mr. Liu Yi (Mr. Liu) will be reassigned as a non-executive director due to work relocation within the group. He will step down from his positions as Chairman, Chairman of the Board Nomination Committee, member of the Board Compensation Committee, and Company Authorized Representative. Mr. Liu will continue to serve as a member of the Nomination Committee. Current Executive Director and CEO, Mr. Lior Moshe Dayan (Mr. Dayan) will assume the roles of Executive Director, Chairman, Chairman of the Nomination Committee, and Authorized Representative. He will no longer hold the position of CEO due to work relocation within the group. Current Non-Executive Director Ms. Feng Rongli will become a member of the Compensation Committee, and current Independent Non-Executive Director Mr. Chen Zhifeng will become a member of the Nomination Committee. Current Global Business President Mr. Eyal BEN DAVID (Mr. Ben David) will become the CEO, and Company Executive Director and CFO Mr. Li Jiahong (Mr. Li) will also concurrently serve as Joint CEO. Mr. Wu Yifang (Mr. Wu) has resigned as a Non-Executive Director of the company effective January 1, 2026, due to work relocation. Ms. Caroline Xiaokui JIN (Ms. Jin) has been appointed as a Non-Executive Director effective January 1, 2026.